Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MORAb-202 |
Synonyms | |
Therapy Description |
MORAb-202 is an anti-folate receptor alpha (FRA) antibody (farletuzumab) in conjugation with eribulin, which may lead to cytotoxic killing of FRA-positive tumors (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B115, PMID: 30262588). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MORAb-202 | MORAb 202|MORAb202 | FOLR1-targeted Therapy 17 | MORAb-202 is an anti-folate receptor alpha (FRA) antibody (farletuzumab) in conjugation with eribulin, which may lead to cytotoxic killing of FRA-positive tumors (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B115, PMID: 30262588). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05613088 | Phase II | Paclitaxel + Pegylated liposomal doxorubicin + Topotecan MORAb-202 | A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Recruiting | USA | ITA | ESP | BEL | 5 |
NCT05577715 | Phase II | MORAb-202 | A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) | Recruiting | USA | FRA | ESP | BEL | 2 |
NCT04300556 | Phase Ib/II | MORAb-202 | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FR alpha)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Recruiting | USA | FRA | 1 |